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Abstract
Background: The INSIG2 rs7566605 and PFKP rs6602024 polymorphisms have been identified as obesity gene variants in
genome-wide association (GWA) studies. However, replication has been contradictory for both variants. The aims of this
study were to validate these obesity-associations through case-control studies and analyses of obesity-related quantitative
traits. Moreover, since environmental and genetic factors may modulate the impact of a genetic variant, we wanted to
perform such interaction analyses. We focused on physical activity as an environmental risk factor, and on the GWA
identified obesity variants in FTO (rs9939609) and near MC4R (rs17782313) as genetic risk factors.
Materials and Methods: The four variants were genotyped in a combined study sample comprising a total of 18,014 subject
ascertained from, the population-based Inter99 cohort (n=6,514), the ADDITION screening cohort (n=8,662), a population-
based study sample (n=680) and a type 2 diabetic patient group (n=2,158) from Steno Diabetes Center.
Results: No association with overweight, obesity or obesity-related measures was shown for either the INSIG2 rs7566605 or
the PFKP rs6602024 variants. However, an interaction between the INSIG2 rs7566605 variant and the level of self-reported
physical activity (pInt=0.004) was observed. A BMI difference of 0.53 (SE 0.42) kg/m
2 was found when comparing physically
passive homozygous C-allele carriers with physically passive G-allele carriers. No interactions between the two variants and
FTO rs9939609 and MC4R rs17782313 were observed.
Conclusions: The INSIG2 rs7566605 and PFKP rs6602024 polymorphisms play no apparent role in the development of
common forms of obesity in the Danish population. However, if replicated, the INSIG2 rs7566605 may influence the level of
BMI in combination with the level of physical activity.
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Introduction
The identification of genetic variants contributing to common
forms of obesity has been challenging using traditional strategies
for selection of candidate genes. However, within the last few years
rapid advancements have made genome-wide association (GWA)
studies feasible and these studies have provided new insight into
the pathogenesis of a number of complex polygenic disorders.
Several GWA studies have been performed on obesity, and have
resulted in the identification of new potential obesity susceptibility
gene variants. The rs7566605 located 10 kb upstream of the
insulin induced gene 2 (INSIG2), was the first common obesity-
related gene variant to be identified through a GWA approach,
including 694 individuals [1]. Approximately 10% of the study
population carried the risk CC-genotype, and were on average 1
body mass index (BMI) unit heavier than heterozygous or
homozygous G-allele carriers. The initial finding was validated
in four out of five replication samples, involving a total of 9,881
individuals, with a combined odds ratio (OR) of 1.22 (1.05–1.42)
under a recessive model [1]. Moreover, an independent GWA
scan, comprising 1,000 unrelated U.S. Caucasians, has observed
an association between the INSIG2 rs7566605 variant and obesity
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been observed in five out of nine independent large cohorts from
eight populations across multiple ethnicities, and a meta-analysis
of all nine cohorts, comprising nearly 17,000 individuals also
confirmed the association [3]. Several other independent studies
have, however, failed to validate the originally proposed
association between rs7566605 and obesity when examining a
total of 28,043 Caucasian [4–9], 2,292 Indian [9,10] or 6,477
Asian individuals [11–13]. INSIG2 is the predominant protein
isoform in adipocytes [14], and regulates the transcription of genes
promoting fatty acid synthesis and adipogenesis [15,16], making
INSIG2 a good biological candidate gene for obesity.
The rs6602024 in the platelet type phosphofructokinase (PFKP)
gene was identified in a GWA scan of obesity-related traits in
4,741 individuals, from a genetically isolated population of
Sardinia, to associate strongly with BMI, body weight and hip
circumference under an additive model [17]. The association was,
however, not validated in independent replication cohorts,
including a total of 3,467 subjects, even though homozygous
carriers of the minor A-allele on average were ,1–3 BMI units
heavier than homozygous carriers of the G-allele [17].
PFKP encodes a phosphofructokinase acting as a key regulatory
enzyme in the glycolysis. Enhanced activity of PFKP might alter
the balance between glycolysis and glycogen production, increas-
ing the glucose utilization and thereby lipogenesis, ultimately
leading to obesity [17–19].
GWA studies have already proved successful and reported
novel, unanticipated genetic variants contributing to disease risk. A
now well-established link to obesity includes variants within the
first intron of the fat mass and obesity associated gene (FTO)
[17,20–22]. The consistency of replication across several samples
of Caucasian origin [23–26] and lately in other ethnic samples
[27,28] has considerably strengthened the important contribution
of FTO to obesity. FTO has upon identification been found to
encode a 2-oxoglutarate-dependent nucleic acid demethylase
[29,30], however, the link between this enzyme and the
development of obesity remains to be elucidated. We have
previously validated the association between the rs9939609 variant
within FTO and obesity measures, and interestingly, an interaction
with physical activity was demonstrated to differentiate the degree
of body fat accumulation between genotype groups [23].
A large-scale meta-analysis of GWA data available for 16,876
individuals identified a variant (rs17782313) mapping 188 kb
downstream of the gene encoding melanocortin-4 receptor (MC4R)
to influence on BMI and the finding were replicated in large-scale
studies of 77,228 individuals, both adults and children, with a
combined OR for obesity of 1.12 (1.08–1.16), p=5.2 610
29 [31].
Although mapping hundreds of kilo bases from the coding sequence
of MC4Rtheidentified variant presumabledisruptthetranscriptional
control of MC4R. MC4R is involved in appetite regulation and
representa compellingbiologicalcandidate,asrare codingmutations
in the gene are a cause of monogenic obesity in humans [32].
Statistically powered replications of GWA findings are essential to
determine the true influence of novel gene variants in the
pathogenesis of polygenic obesity. Therefore, the aims of the present
studyare to validate theobesity-associationswith the GWAidentified
INSIG2 rs7566605 and PFKP rs6602024 variants, through case-
control studies and analyses of obesity-related quantitative traits.
Further, since gene-environment and gene-gene interactions may
modulate the effect the variants exert on BMI, analyses are extended
to investigate such interactions, focusing on physical activity as an
environmental risk factor and on GWA identified obesity variants,
reaching a stringent genome-wide significance threshold, (FTO
rs9939609 and MC4R rs17782313) as genetic risk factors.
Materials and Methods
Study samples
The INSIG2 rs7566605 and PFKP rs6602024 variants were
genotyped in 18,014 subjects ascertained from four different study
groups; 1) the Inter99 cohort, which is a population-based,
randomized, non-pharmacological intervention study of middle-
aged subjects for the prevention of ischemic heart disease
(n=6,514), conducted at the Research Centre for Prevention
and Health in Glostrup, Copenhagen (ClinicalTrials.gov ID-no:
NCT00289237) [33]; 2) the ADDITION screening cohort,
Denmark (Anglo–Danish–Dutch Study of Intensive Treatment
in People with Screen-Detected Diabetes in Primary Care)
(ClinicalTrials.gov ID-no: NCT00237548) [34], which is a
population-based, high-risk screening and intervention study for
type 2 diabetes in general practice (n=8,662); 3) a population-
based group of unrelated middle-aged subjects (n=680) examined
at Steno Diabetes Center; and 4) unrelated type 2 diabetic patients
(n=2,158) sampled through the out-patient clinic at Steno
Diabetes Center. The combined study sample refers to the
combination of these four study groups. In the combined study
sample 1,914 had screen-detected and 2,302 had known type 2
diabetes, 5,512 were normal weight, 7,458 were overweight and
5,044 were obese. All participants in study group 1 and 3
underwent a standard 75 g oral glucose tolerance test. Type 2
diabetes was defined according to the World Health Organization
[35]. Overweight and obesity were defined as 25#BMI,30 and
BMI$30 kg/m
2, respectively. All study participants were Danes
by self-report. Informed written consent was obtained from all
subjects before participation. The studies were approved by the
regional Ethics Committees (ethics committee, Copenhagen
County for study group 1,3 and 4 and ethics committee, Aarhus
County for study group 2) and were in accordance with the
principles of the Helsinki Declaration.
Biochemical and anthropometrical measurements
In all four study groups body weight and height were measured
in light indoor clothes and without shoes. BMI was defined as
weight in kilograms divided by height in meters squared (kg/m
2).
Waist circumference (cm) was measured with subjects in standing
position midway between the iliac crest and the lower costal
margin. In study group 1, 3 and 4 blood samples were drawn after
a 12-hour overnight fast and serum triglycerides, total cholesterol
and high density lipoprotein (HDL) -cholesterol were determined
using enzymatic colourimetric methods (GPO-PAP and CHOD-
PAP; Roche Molecular Biochemicals, Mannheim, Germany).
Serum insulin levels excluding des(31,32)- and intact proinsulin
were measured using the AutoDELFIA insulin kit (Perkin-Elmer,
Wallac, Turku, Finland). Plasma glucose was analysed using a
glucose oxidase method (Granutest; Merck, Darmstadt, Germany)
[36]. The level of physical activity in study group 1 was self-
reported by questionnaire and divided into five categories as;
physically passive and light, medium, hard or very hard physically
active [36]. These categories were combined in two ways in the
analyses; three groups defined as physically passive, light or
medium physically active, hard or very hard physically active, and
in two groups defined as physically passive and physically active
including all four levels of physical activity.
Genotyping
The INSIG2 rs7566605 and PFKP rs6602024 variants were
genotyped in the combined study sample using Taqman allelic
discrimination (KBioscience, Herts, UK). The discordances
between 686 random duplicate samples were 0.3% and 0.0%
INSIG2/PFKP Variants & Obesity
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variants, and the minor allele frequencies (MAF) were 32.9%
and 10.8%, respectively. The FTO rs9939609 and MC4R
rs17782313 variants used in the gene-gene interaction analyses
were genotyped using the same technique. The discordances
between 1,464 and 721 random duplicate samples were 0.3% and
0.0% respectively. Genotyping success rates were 97.4% and
95.8%, and the MAF were 41.5% and 25.2%, respectively. All
genotype groups obeyed Hardy-Weinberg equilibrium.
Statistical analyses
In case-control studies of overweight and obesity, logistic
regression was applied to examine differences in genotype
distributions between affected and unaffected subjects, applying
a recessive model for the INSIG2 rs7566605 variant, and an
additive model for the PFKP rs6602024 variant. Adjustments for
age, sex and study group were introduced analysing the combined
study sample, and for age and sex when analysing the population-
based Inter99 study sample. A general linear model was used to
test quantitative traits for differences between genotype groups
applying the prior stated genetic model for each variant.
Adjustment for sex, age, study group and BMI was applied when
appropriate. Linear models extended with environmental param-
eters were used to test for gene-environment interactions using an
analysis of variance (ANOVA) test, treating physical activity as a
categorical variable. Likewise, additional genetic parameters were
added to a linear model, when analysing gene-gene interactions
with GWA identified obesity variants. All analyses were performed
in RGui version 2.6.2 [37]. p-values,0.05 were considered
significant. A test for homogeneity between the Inter99 cohort,
the ADDITION cohort, the population-based and type 2 diabetic
patient group from Steno Diabetes Center, was performed by
means of the Mantel-Haenszel method (fixed effects model),
revealing no significant heterogeneity between the study groups
(p=0.5). Statistical power was determined using the CaTS power
calculator version 0.0.2. To get robust p-values for the gene-
environment and gene-gene interactions, we used a permutation
procedure where the phenotype labels where randomly permuted
between individuals. The lowest p-value from all iterations
(n=1,000) were saved, and used as an empirical distribution to
obtain robust p-values which are corrected for multiple testing.
Results
Using the population-based Inter99 cohort as reference, we
found that the prevalence of overweight and obesity was 39% and
17%, respectively, in the Danish population. This gives us a
statistical power of 100% observing association between a variant
with a MAF of 10% and both overweight and obesity with a
relative risk of 1.2, applying an additive model. For a variant with
a MAF of 30%, we have a statistical power of 97% and 72%
observing an association between overweight and obesity respec-
tively with a relative risk of 1.2, when applying a recessive model.
Potential associations of the INSIG2 rs7566605 C-allele and the
PFKP rs6602024 A-allele with overweight and obesity were
evaluated by performing case-control studies in the combined
study sample and further in the population-based Inter99 cohort,
to elucidate the effect on a population-based level, however, no
association was observed (Table 1).
The two variants were furthermore investigated for influence on
quantitative obesity-related traits in the combined study sample
and in the population-based Inter99 cohort excluding known type
Table 1. Case-control study of the INSIG2 rs7566605 and PFKP rs6602024 variants in relation to overweight and obesity.
INSIG2 rs7566605 n (men/women) Genotype distribution n GG/GC/CC (%) MAF (95% CI) prec ORrec (95% CI)
Combined study sample* (n=16,781)
Controls 5,106 (2,113/2,993) 2,264/2,274/568 (44/45/11) 33.4 (32.5–34.3)
Overweight cases 6,973 (4,332/2,641) 3,162/3,056/755 (45/44/11) 32.7 (32.0–33.5) 0.7 0.98 (0.87–1.10)
Obese cases 4,702 (2,425/2,277) 2,118/2,077/507 (45/44/11) 32.9 (31.9–33.8) 0.8 1.02 (0.89–1.16)
Population-based Inter99 cohort** (n=6,158)
Controls 2,708 (1,038/1,670) 1,176/1,225/307 (44/45/11) 34.0 (32.7–35.2)
Overweight cases 2,391 (1,449/942) 1,079/1,060/252 (45/44/11) 32.7 (31.4–34.1) 0.4 0.92 (0.77–1.10)
Obese cases 1,059 (524/535) 472/454/133 (44/43/13) 34.0 (32.0–36.1) 0.2 1.15 (0.93–1.44)
PFKP rs6602024 n (men/women) Genotype distribution n GG/GA/AA (%) MAF (95% CI) padd ORadd
Combined study sample* (n=16,741)
Controls 5,095 (2,110/2,985) 4,054/980/61 (80/19/1) 10.8 (10.2–11.4)
Overweight cases 6,971 (4,334/2,637) 5,599/1,302/70 (80/19/1) 10.3 (9.8–10.9) 0.1 0.93 (0.85–1.01)
Obese cases 4,675 (2,399/2,276) 3,680/947/48 (79/20/1) 11.2 (10.5–11.8) 0.7 1.02 (0.92–1.12)
Population-based Inter99 cohort** (n=6,144)
Controls 2,700 (1,035/1,665) 2,176/493/31 (81/18/1) 10.3 (9.5–11.1)
Overweight cases 2,386 (1,443/943) 1,949/413/24 (82/17/1) 9.7 (8.8–10.5) 0.2 0.92 (0.81–1.05)
Obese cases 1,058 (522/536) 835/213/10 (79/20/1) 11.0 (9.7–12.4) 0.4 1.07 (0.91–1.26)
Data are number of subjects, divided into genotype groups (% in each group), frequencies of the minor allele (MAF) in percentages (95% CI) and odds ratio (OR) for the
applied genetic model (95% CI). Differences in genotype distribution was evaluated using logistic regression, applying a recessive model (prec) for the INSIG2 rs7566605
variant (GG/GC vs. CC) and an additive model (padd) for the PFKP rs6602024 variant (GG vs. GA vs. AA).
*In the combined study sample (where all four study groups, the
Inter99 cohort, the ADDITION cohort, the SDC population-based and type 2 diabetes sample were included) p-values were adjusted for age, sex, and study group,
whereas p-values in the
**population-based Inter99 cohort were adjusted for age and sex. Controls were defined as BMI,25, overweight cases as 25#BMI,30 and
obese cases as BMI$30 kg/m
2 respectively.
doi:10.1371/journal.pone.0002872.t001
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body weight or waist circumference could be shown (Table 2).
Since the INSIG2 rs7566605 C-allele has been proposed to exert a
larger effect in individuals already predisposed to obesity, we
investigated the effect of the variant in the obese subgroup of the
combinedstudysample(n=3,878),with a mean BMI of 32.8kg/m
2,
however, no genotype effect was found (data not shown).
In the population-based Inter99 cohort, serum insulin and plasma
glucosemeasures during an oral glucosetolerance testwereavailable,
together with fasting levels of serum triglyceride and HDL-
cholesterol. However, none of these measures were associated with
INSIG2 rs7566605 or PFKP rs6602024 genotypes (data not shown).
In analyses of gene-environment interactions comprising a total of
5,604 individuals from the population-based Inter99 cohort,
excluding known type 2 diabetes patients, we found an interaction
between INSIG2 rs7566605 genotype and the level of self-reported
physical activity. When dividing subjects into three groups
categorised as physically passive, light or medium physically active
and hardorveryhardphysicallyactive,adifferenceinBMIlevelwas
only observed between the group of physically passive homozygous
C-allelecarriers and physically passiveG-allelecarriers (pInt=0.004).
No difference in BMI was observed between genotype groups for
light or medium physically active or hard or very hard physically
active. Therefore, we tested physically passive against physically
active (light to very hard physically active) (pInt=0.004), and found
that physically passive homozygous C-allele carriers had a BMI 1.00
(SE 0.46) kg/m
2 higher than physically active homozygous C-allele
carriers whereas physically passive G-allele carriers only had a BMI
0.54 (SE 0.14) kg/m
2 higher than physically active G-allele carriers
(Figure 1). This is also reflected in a difference of 0.53 (SE 0.42) kg/
m
2 between physically passive homozygous C-allele carriers and
physically passive G-allelecarriers. The robustness of the p-value was
verified by the empirical value obtained by the permutation
procedure (p=0.005). No interaction between the PFKP rs6602024
variant and physical activity was demonstrated.
We further investigated potential interactions between the
rs7566605 and rs66020245 variants and GWA identified obesity
variants reaching the stringent significance threshold; rs9939609
located in FTO and rs17782313 located downstream from MC4R,
however, no interactions were observed (data not shown).
Discussion
Analysing 18,014 Danish individuals, we failed to demonstrate a
correlation between the INSIG2 rs7566605 C-allele and the PFKP
Table 2. Quantitative obesity-related traits in the combined study sample and the population-based Inter99 cohort.
INSIG2 rs7566605 PFKP rs6602024
GG GC CC prec GG GA AA padd
Combined study sample*
n (men/women) 6,658 (3,482/3,176) 6,552 (3,467/3,085) 1,619 (836/783) 11,806 (6,177/5,629) 2,840 (1,513/1,327) 150 (71/79)
Age (years) 55610 55610 54610 54610 55610 55610
BMI (kg/m
2) 27.664.8 27.564.9 27.565.0 0.9 27.564.9 27.664.9 27.665.3 0.8
Body weight (kg) 81.1616.2 81.1616.2 80.9616.7 0.9 81.0616.2 81.3616.6 79.4615.3 1
Waist (cm) 92.7614.4 92.5614.1 92.3614.6 0.9 92.5614.2 93.0614.4 91.7615.5 0.6
Population-based Inter99 cohort**
n (men/women) 2,559 (1,271/1,288) 2,559 (1,282/1,277) 652 (317/335) 4,642 (2,303/2,339) 1,056 (532/524) 60 (25/35)
Age (years) 46684 6 684 6 684 6 684 6 684 6 68
BMI (kg/m
2) 26.264.5 26.164.5 26.464.5 0.2 26.264.5 26.364.7 25.964.2 0.9
Body weight (kg) 78.0615.7 78.0615.9 78.3617.2 0.4 78.1615.9 78.3616.4 75.1613.4 0.9
Waist (cm) 86.5613.2 86.4613.1 86.7613.9 0.4 86.4613.2 87.0613.3 84.4612.4 0.6
Data are means6standard deviation. p-values were calculated assuming a recessive model (prec)f o rINSIG2 rs7566605 variant (GG/GC vs. CC) and an additive model
(padd)f o rPFKP rs6602024 variant (GG vs. GA vs. AA) in the combined study sample (where all four study groups, the Inter99 cohort, the ADDITION cohort, the SDC
population-based and type 2 diabetes sample were included) and the population-based Inter99 cohort. Known type 2 diabetic patients were excluded from the
analyses.
*Adjustments for the effect of age, sex and study group was introduced for the combined study sample, and for age and sex in the
**population-based Inter99
cohort.
doi:10.1371/journal.pone.0002872.t002
Figure 1. Effect of physical activity on the impact of the INSIG2
rs7566605 genotype on BMI. Participants (n=5,604) from the
population-based Inter99 cohort, were divided according to self-
reported physical activity categorised as physically passive and
physically active and stratified according to INSIG2 rs7566605 genotype
applying a recessive model. Bars indicate mean BMI, and error bars
indicate standard error. The number of participants (physically passive/
physically active) are (1,712/3,259) for G-allele carriers and (202/431) for
homozygous C-allele carriers. We tested for interaction effects using
linear models, with or without, interaction parameters for physical
activity compared by an ANOVA test (pInt=0.004).
doi:10.1371/journal.pone.0002872.g001
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case-control studies of overweight and obesity, and when analysing
quantitative obesity-related traits. The obesity-association of PFKP
rs6602024 was not successfully replicated in the initial GWA
study, which was suggested to be due to the relatively low risk
allele frequency of the variant resulting in only a small fraction of
the population being affected. However, the variant exerted a
relatively large effect size on BMI in the replication cohorts, with
homozygous A-allele carriers having a BMI ,3 units higher than
G-allele carriers, and therefore it was proposed that larger
population samples might be needed in order to reach statistical
significance [17]. We did, however, not replicate the association
between PFKP rs6602024 and obesity measures, either using an
additive or recessive model. On the contrary we observed slightly
lower BMI, body weight and waist circumference among
homozygous PFKP rs6602024 A-allele carriers. The failure to
replicate the association between PFKP rs6602024 and different
measures of obesity in the present study could be due to differences
in linkage disequilibrium patterns between the population in which
the variant was first identified [17] and our study material. An
independent GWA study in unrelated U.S. Caucasians has
reported an association between three other polymorphisms in
PFKP and excessive body fat accumulation [2]. Hence, PFKP could
in theory be a true obesity susceptibility gene, with rs6602024
failing to be a marker for the functional variant in our population.
Several studies have failed to validate the initial GWA finding of
the INSIG2 rs7566605 C-allele contributing to the pathogenesis of
obesity. Despite the large-scale study samples included in our study,
we were not able to confirm the proposed association, in neither
case-control nor quantitative settings. The effect of the INSIG2
rs7566605 variant on BMI has been proposed to be predominant in
already obese subjects, but neither in an obese subgroup did we
observe an association. However, the effect of some genetic variants
is only exerted in combination with environmental or other genetic
risk factors [38]. When taking the level of physical activity into
account, we detected an INSIG2 rs7566605 genotype effect on the
level of BMI. Physical inactivity results in an increased BMI level in
bothG-allelecarriersandhomozygousC-allelecarriers.Inthegroup
of G-allele carriers the effect of physical inactivity on BMI level is
0.54 (SE 0.14) kg/m
2, whereas the effect is more pronounced in
homozygous C-allele carriers increasing the BMI level by 1.00 (SE
0.46) kg/m
2. This indicates an interaction between the INSIG2
rs7566605 variant and physical activity. This is supported by the
observation that the BMI level in the subgroup of physically passive
is 0.53 (SE 0.42) kg/m
2 higher in homozygous C-allele carries
compared with physically passive G-allele carriers. However, this
interaction analysis is merely explorative, since it is based on self-
reported measures, and replication in statistically well-powered
populations with more precise physiological physical activity
measures is imperative.
We can thus conclude that common variation in INSIG2 and
PFKP, both candidate genes arising from GWA studies, do not
play a significant role in the pathogenesis of obesity in the Danish
population. Still, if replicated common variation in INSIG2 might,
contribute to common forms obesity through interaction with a
low level of physical activity.
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